Movement Alert｜AbbVie Rises 3.01% in Regular Trading, Multiple Investment Banks Raise Price Targets

Market Focus

Jul 16

On July 16, AbbVie rose 3.01% in regular trading, trading at approximately $251.72 per share, with turnover of $2.33 billion. The rally was driven by a wave of Wall Street price target upgrades over recent sessions.

On the news front, several major investment banks raised their price targets on AbbVie in quick succession. Citigroup lifted its target to $260 from $230 on July 15, while UBS similarly raised to $260 from $230. Bank of America significantly increased its target to $276 from $234, naming AbbVie a top pick in biopharma. RBC Capital Markets maintained an outperform rating and raised its target to $280 from $260, citing improved sentiment following the recent Apogee acquisition. FactSet consensus shows an average overweight rating with a mean price target of $266.60. The upgrades come ahead of AbbVie's Q2 earnings report scheduled for July 31, with analysts expecting adjusted EPS of $3.57-$3.61 after factoring in $291 million of acquired IPR&D expenses disclosed in a recent guidance update.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1143938691"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143938691\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143938691?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143938691","market":"us","top_or_hot":-1,"title":"Movement Alert｜AbbVie Rises 3.01% in Regular Trading, Multiple Investment Banks Raise Price Targets","media":"Market Focus","content":"<p><p>On July 16, AbbVie rose 3.01% in regular trading, trading at approximately $251.72 per share, with turnover of $2.33 billion. The rally was driven by a wave of Wall Street price target upgrades over recent sessions.</p><p>On the news front, several major investment banks raised their price targets on AbbVie in quick succession. Citigroup lifted its target to $260 from $230 on July 15, while UBS similarly raised to $260 from $230. Bank of America significantly increased its target to $276 from $234, naming AbbVie a top pick in biopharma. RBC Capital Markets maintained an outperform rating and raised its target to $280 from $260, citing improved sentiment following the recent Apogee acquisition. FactSet consensus shows an average overweight rating with a mean price target of $266.60. The upgrades come ahead of AbbVie's Q2 earnings report scheduled for July 31, with analysts expecting adjusted EPS of $3.57-$3.61 after factoring in $291 million of acquired IPR&D expenses disclosed in a recent guidance update.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AbbVie Rises 3.01% in Regular Trading, Multiple Investment Banks Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AbbVie Rises 3.01% in Regular Trading, Multiple Investment Banks Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 22:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, AbbVie rose 3.01% in regular trading, trading at approximately $251.72 per share, with turnover of $2.33 billion. The rally was driven by a wave of Wall Street price target upgrades over recent sessions.</p><p>On the news front, several major investment banks raised their price targets on AbbVie in quick succession. Citigroup lifted its target to $260 from $230 on July 15, while UBS similarly raised to $260 from $230. Bank of America significantly increased its target to $276 from $234, naming AbbVie a top pick in biopharma. RBC Capital Markets maintained an outperform rating and raised its target to $280 from $260, citing improved sentiment following the recent Apogee acquisition. FactSet consensus shows an average overweight rating with a mean price target of $266.60. The upgrades come ahead of AbbVie's Q2 earnings report scheduled for July 31, with analysts expecting adjusted EPS of $3.57-$3.61 after factoring in $291 million of acquired IPR&D expenses disclosed in a recent guidance update.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABBV","symbol_name":"艾伯维公司","start_time":0,"source_url":"","article_id":"1143938691","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143938691","pubTimestamp":1784212041,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, AbbVie rose 3.01% in regular trading, trading at approximately $251.72 per share, with turnover of $2.33 billion. The rally was driven by a wave of Wall Street price target upgrades over...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABBV":"艾伯维公司"},"translate_title":"走势提醒|艾伯维常规交易上涨3.01%，多家投行上调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1},"content_text":"On July 16, AbbVie rose 3.01% in regular trading, trading at approximately $251.72 per share, with turnover of $2.33 billion. The rally was driven by a wave of Wall Street price target upgrades over recent sessions.On the news front, several major investment banks raised their price targets on AbbVie in quick succession. Citigroup lifted its target to $260 from $230 on July 15, while UBS similarly raised to $260 from $230. Bank of America significantly increased its target to $276 from $234, naming AbbVie a top pick in biopharma. RBC Capital Markets maintained an outperform rating and raised its target to $280 from $260, citing improved sentiment following the recent Apogee acquisition. FactSet consensus shows an average overweight rating with a mean price target of $266.60. The upgrades come ahead of AbbVie's Q2 earnings report scheduled for July 31, with analysts expecting adjusted EPS of $3.57-$3.61 after factoring in $291 million of acquired IPR&D expenses disclosed in a recent guidance update.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}